arrow
S

Spyridon Gkalpakiotis

Charles University
H指数:17
被引数:983

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study

特应性皮炎患者接受先进系统性治疗时调节性安全风险因素的流行率:一项国际真实世界研究

2026-09-120
PRE
Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study

Rezpegaldesleukin治疗中重度特应性皮炎(REZOLVE-AD):一项国际性、双盲、安慰剂对照、随机期2b研究的16周诱导期最终结果

2026-08-220
PRE
Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort

特应性皮炎的临床试验入组标准:来自大型国际真实世界队列的数据

2026-01-050
OAAI
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry

银屑病患者从IL-23抑制剂转换为IL-17抑制剂后的疗效和药物生存率:BIOREP登记研究分析

2026-01-010
OA
REZPEGALDESLEUKIN, NOVEL TREG-INDUCING THERAPY, DEMONSTRATES EFFICACY IN ATOPIC DERMATITIS AND ASTHMA IN PHASE 2B TRIAL

REZPEGALDESLEUKIN,一种新型Treg诱导疗法,在2b期临床试验中显示出对特应性皮炎和哮喘的有效性。

2025-11-050
PRE
Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis

不同Lebrikizumab剂量在特应性皮炎患者中的疗效与安全性评价(16至24周):一项BIOREP注册登记研究

2025-11-010
OA
Super-Response to Guselkumab Treatment in Patients With Moderate-to-Severe Psoriasis: Real-World Data With Up to Five Years of Follow-Up in The Czech Republic

中重度银屑病患者对 guselkumab 治疗的超应答:来自捷克共和国的真实世界数据,随访期长达五年

2025-10-310
OAAI
Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry

度普利尤单抗在特应性皮炎中24周的有效性与安全性:BIOREP登记研究的一项分析

2025-08-130
PRE
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study

度普利尤单抗、特拉斯库单抗和乌帕替尼在特应性皮炎患者中的药物生存率:一项国际性、真实世界比较研究

2025-02-063
OA
A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
2024-08-080
PRE
Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study
2024-06-110
PRE
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

tralokinumab治疗的大多数特应性皮炎患者实现了当前的治疗目标: 多中心,跨国,回顾性队列研究的结果

2023-12-186
PRE